Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting

Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting

SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced data from the Phase 2 ORCA-V1 vaping cessation trial will be presented today, Friday, May 17, 2024, at the Society of General Internal Medicine (SGIM) Annual Meeting being held in Boston, MA. Dr. Nancy Rigotti, ORCA-V1 Principal Investigator and Professor of Medicine at Harvard Medical School, and Director of the Tobacco Research and Treatment Center at Massachusetts General Hospital, will present data from the Phase 2 ORCA-V1 trial. This study explored the efficacy and safety of cytisinicline in adult smokers seeking to quit nicotine e-cigarettes....

Continue reading

Spectral AI Announces Purchases of Over 100,000 Shares by Insiders

Spectral AI Announces Purchases of Over 100,000 Shares by Insiders

DALLAS, May 17, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that several of the Company’s officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions on May 10, 2024 and May 15, 2024. The Company continues to make significant strides toward commercializing its proprietary DeepView™ System, an AI-driven predictive medical device that delivers an immediate and objective assessment of a wound’s healing potential. Initial applications involve patients with burns and diabetic foot ulcers (DFU). In February, the Company received UKCA Authorization to commence sales of its DeepView™...

Continue reading

Blockchain AI Market to Surpass USD 2346.68 million by 2031 | SkyQuest Technology

Blockchain AI Market to Surpass USD 2346.68 million by 2031 | SkyQuest Technology

Westford,USA, May 17, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Blockchain AI Market will attain a value of USD 2346.68 million by 2031, with a CAGR of 23.6% over the forecast period (2024-2031). The blockchain technology industry has grown as a result of the increasing demand for effective data access and management. Everyone is doing their work using digital systems at present and files most of the information on the internet, cloud type where it will be easy accessed and maintained by Blockchain AI. This is due to Blockchain AI concern themselves with content and value, thus, making it inevitable for these two technologies to merge. When it comes to safe data passing and storing capabilities then blockchain technology is all that one requires yet Artificial Intelligence can utilize data analysis along with providing insight...

Continue reading

Phoenix Group PLC Posts Stellar 2024 First Quarter Results with Surge in Assets and Profits

Phoenix Group PLC Posts Stellar 2024 First Quarter Results with Surge in Assets and Profits

Dubai, UAE, May 17, 2024 (GLOBE NEWSWIRE) — Phoenix Group PLC (ADX:PHX), the leading provider of web3, crypto, and blockchain technologies in the region, has announced impressive financial results for the first quarter of 2024. Building on a successful inaugural year as a publicly traded entity, the company has showcased the robustness of its business model and its steadfast commitment to enhancing stakeholder value.  In the first year as a publicly listed company, Phoenix Group is proud to announce a Q1 net income of USD 66.2 million, a growth of 166% year-on-year. Key financial highlights: ⁠Total assets surged by 237% year-over-year, soaring to $879.3 million from $261 million. ⁠The quarter-over-quarter growth in total assets stands at 5%. Revenue experienced an 18% quarter-on-quarter increase, reaching $68.9 million....

Continue reading

Partners Value Investments Inc. Announces Q1 2024 Interim Results

Partners Value Investments Inc. Announces Q1 2024 Interim Results

TORONTO, May 17, 2024 (GLOBE NEWSWIRE) — Partners Value Investments Inc. (the “Company”, TSX: PVF.WT, PVF.PR.V) announced today its financial results for the three months ended March 31, 2024. All amounts are stated in U.S. dollars. The Company recorded a net loss of $175 million for the three months ended March 31, 2024, compared to net income of $242 million in the prior year quarter. The net loss was primarily due to current period remeasurement losses of $214 million associated with the retractable shares, compared to remeasurement gains of $226 million in the prior year quarter. The Company’s retractable common shares are classified as liabilities due to their cash retraction feature. The remeasurement gains or losses in a given period are driven by the respective depreciation or appreciation of the Partners Value Investments...

Continue reading

Partners Value Investments L.P. Announces Q1 2024 Interim Results

Partners Value Investments L.P. Announces Q1 2024 Interim Results

TORONTO, May 17, 2024 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”, TSX: PVF.UN TSX:PVF.PR.U) announced today its financial results for the three months ended March 31, 2024. All amounts are stated in U.S. dollars. The Partnership recorded net income of $26.3 million for the three months ended March 31, 2024, compared to net income of $7.3 million in the prior year quarter. The increase in income was primarily driven by the higher dividend income, foreign currency gains and tax recoveries. Income of $24.7 million was attributable to the Equity Limited Partners, and $1.6 million was attributable to Preferred Limited Partners. As at March 31, 2024, the market prices of a Brookfield Corporation (NYSE/TSX: BN) and Brookfield Asset Management Ltd. (the “Manager”, NYSE/TSX: BAM) share were $41.87 and $42.02,...

Continue reading

Rapala VMC strengthens is sustainability commitments by joining UN Global Compact

Rapala VMC strengthens is sustainability commitments by joining UN Global Compact

PRESS RELEASE, May 17, 2024 Rapala VMC Corporation proudly announces that it has been accepted as participant in the United Nations Global Compact. By aligning with global standards, Rapala VMC aims to amplify its efforts in environmental stewardship and social responsibility. Seeking membership in the UN Global Compact allows the company to leverage the expertise and resources of this esteemed organization to further its sustainability agenda. Driven by evolving regulations, particularly in the European Union, Rapala VMC acknowledges the importance of aligning with established organizations promoting sustainable practices. Joining the UN Global Compact demonstrates the company’s proactive stance in meeting regulatory requirements and embracing best practices. “We believe that sustainable business practices and social responsibility...

Continue reading

Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future – 4,000mg highest dosage to date in this clinical trial RECCE® 327 (R327) tested at four fast IV infusion times (15-mins, 20-mins, 30-mins, 45-mins) over various dosage levels Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples, a dose optimization exercise for regulatory purposes SYDNEY, Australia, May 17, 2024 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it dosed the first male and female participants at 4,000mg over 20 minutes in the next cohort of a Phase I/II urinary tract infection/urosepsis trial, evaluating its lead...

Continue reading

LGI Homes Announces the Grand Opening of Cambridge Cove, A New Community North of Minneapolis

LGI Homes Announces the Grand Opening of Cambridge Cove, A New Community North of Minneapolis

The Henry at Cambridge Cove by LGI Homes Cambridge Cove by LGI Homes offers a variety of brand-new, move-in ready homes located off MN-65 in Cambridge. CAMBRIDGE, Minn., May 17, 2024 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced the grand opening of Cambridge Cove, a new single-family home community located north of Minneapolis in Cambridge. Of the six plans built by LGI Homes at this community, five are brand-new to the Minneapolis market. Cambridge Cove’s convenient location off MN-65 provides homeowners with commuter access to the employment and attractions offered on the north side of Minneapolis, as well as proximity to an array of local amenities in Cambridge and nearby cities. “We are excited to introduce Cambridge Cove, our first LGI Homes community in Cambridge, Minnesota. This community complements...

Continue reading

DSV, 1110 - MAJOR SHAREHOLDER ANNOUNCEMENT

DSV, 1110 – MAJOR SHAREHOLDER ANNOUNCEMENT

Company Announcement No. 1110 Pursuant to section 30 of the Danish Capital Markets Act it is announced that BlackRock, Inc. has informed DSV A/S that the total shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2) of the Danish Capital Markets Act of DSV A/S held by BlackRock, Inc. as of 14 May 2024 correspond to below 5% of the entire share capital and below 5% of the voting rights of DSV A/S. ContactsInvestor Relations: Sebastian Rosborg, tel. +45 43 20 33 87, sebastian.rosborg@dsv.com Yours sincerely,DSV A/S Attachment 1110 – Announcement (17.05.2024) – Major shareholder announcement

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.